Payment overview · 2025
General Payments
$70,387.72
317 reported records · 34 companies
Healthcare provider profile · identity verified
Matthew C. Holtzman, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · WAYNE, MI · NPI 1275741647
Verified facts
What the public records show
CMS Open Payments records show Matthew C. Holtzman, M.D. received $70,387.72 in general payments during 2025 across 317 reported records.
ABBVIE INC. accounted for 80.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ampyra, Austedo Xr, Epidiolex, Firdapse, Fycompa, Qulipta, Rexulti, Ubrelvy, Vraylar, Xcopri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Nuplazid by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FIRDAPSE as an associated drug or biological on 1474 records involving 920 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Firdapse by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Fycompa by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Actemra as an associated drug or biological on 2116 records involving 1314 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Actemra by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Enspryng as an associated drug or biological on 186 records involving 143 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Enspryng by this doctor in 2024.
Genentech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Enspryng as an associated drug or biological on 12 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Enspryng by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Epidiolex by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ampyra by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Gammagard Liquid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56,676.44 | 80.5% | 126 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$8,451.84 | 12.0% | 20 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $1,007.94 | 1.4% | 8 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $492.53 | 0.7% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $339.70 | 0.5% | 7 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $331.12 | 0.5% | 14 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $292.73 | 0.4% | 15 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $272.60 | 0.4% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $257.68 | 0.4% | 11 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $221.27 | 0.3% | 14 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $204.13 | 0.3% | 6 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $197.19 | 0.3% | 3 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $192.51 | 0.3% | 2 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $171.73 | 0.2% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $165.07 | 0.2% | 11 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $141.03 | 0.2% | 6 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $140.24 | 0.2% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $137.69 | 0.2% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $98.28 | 0.1% | 4 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.28 | 0.1% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $64.85 | 0.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.51 | 0.1% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $51.98 | 0.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43.75 | 0.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.00 | 0.1% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.87 | 0.1% | 5 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.00 | 0.1% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $29.81 | 0.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $29.00 | 0.0% | 1 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $25.78 | 0.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $24.61 | 0.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $23.82 | 0.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.95 | 0.0% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.79 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,500.00 | 10 |
| Consulting Fee | $14,787.50 | 7 |
| Travel and Lodging | $9,074.91 | 22 |
| Food and Beverage | $7,066.06 | 267 |
| Honoraria | $6,750.00 | 5 |
| Education | $209.25 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33,025.17 | 79 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19,353.71 | 65 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $7,947.09 | 9 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $921.53 | 14 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $345.18 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $323.55 | 19 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $305.49 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $257.68 | 11 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc., Genentech, Inc. | $252.92 | 4 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $248.71 | 6 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $221.27 | 14 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $202.01 | 11 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $200.28 | 6 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $171.73 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $165.07 | 11 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $159.88 | 5 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $141.03 | 6 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $137.69 | 5 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $122.53 | 5 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $109.70 | 6 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC., Octapharma USA, Inc., PFIZER INC. | $107.90 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $98.28 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $86.28 | 4 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | HOSPIRA, INC., PFIZER INC. | $83.29 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $74.93 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $72.32 | 3 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $64.85 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $61.72 | 5 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $51.98 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $47.19 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $44.25 | 1 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $43.75 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $41.78 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $41.78 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $41.00 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $40.87 | 5 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $34.00 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $30.54 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $29.00 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $25.63 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AMPYRA ampyra |
2025 | Ampyra | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FIRDAPSE firdapse |
2025 | Firdapse | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 133 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 46 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FIRDAPSE open payments reported associated product |
CMS Open Payments — General Payments 1474 supporting records · 920 recipient NPIs · example record 1253216494 |
Firdapse · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
133 | 20 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Actemra open payments reported associated product |
CMS Open Payments — General Payments 2116 supporting records · 1314 recipient NPIs · example record 1211488494 |
Actemra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Enspryng open payments reported associated product |
CMS Open Payments — General Payments 186 supporting records · 143 recipient NPIs · example record 1211488510 |
Enspryng · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Genentech, Inc. Exact reporting entity; no affiliate inference |
2025 | Enspryng open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 9 recipient NPIs · example record 1211492995 |
Enspryng · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pregabalin | Pregabalin | 415 | 86 |
| Duloxetine Hcl | Duloxetine Hcl | 209 | 45 |
| Levetiracetam | Levetiracetam | 200 | 40 |
| Gabapentin | Gabapentin | 159 | 44 |
| Topiramate | Topiramate | 147 | 43 |
| Donepezil Hcl | Donepezil Hcl | 141 | 37 |
| Lamotrigine | Lamotrigine | 139 | 25 |
| Memantine Hcl | Memantine Hcl | 136 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 35 |
| Fycompa | Perampanel | 133 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 130 | 32 |
| Aptiom | Eslicarbazepine Acetate | 129 | 16 |
| Lacosamide | Lacosamide | 120 | 20 |
| Dalfampridine Er | Dalfampridine | 101 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 100 | 32 |
| Aimovig Autoinjector | Erenumab-Aooe | 90 | 16 |
| Aripiprazole | Aripiprazole | 85 | 25 |
| Oxcarbazepine | Oxcarbazepine | 85 | 25 |
| Bupropion Xl | Bupropion Hcl | 79 | 21 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 79 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 77 | suppressed |
| Primidone | Primidone | 76 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 72 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 16 |
| Baclofen | Baclofen | 65 | 18 |
| Zonisamide | Zonisamide | 65 | 11 |
| Xcopri | Cenobamate | 61 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 54 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 53 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 16 |
| Vraylar | Cariprazine Hcl | 52 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 49 | suppressed |
| Clonazepam | Clonazepam | 47 | 11 |
| Rasagiline Mesylate | Rasagiline Mesylate | 47 | 13 |
| Ubrelvy | Ubrogepant | 46 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 45 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | 16 |
| Qulipta | Atogepant | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 37 | suppressed |
| Alprazolam | Alprazolam | 36 | suppressed |
| Verapamil Sr | Verapamil Hcl | 35 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Prednisone | Prednisone | 34 | 12 |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 33 | suppressed |
| Ingrezza | Valbenazine Tosylate | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Amantadine | Amantadine Hcl | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Clobazam | Clobazam | 28 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Rytary | Carbidopa/Levodopa | 25 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Levetiracetam Er | Levetiracetam | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 22 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 17 | suppressed |
| Ampyra | Dalfampridine | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Famotidine | Famotidine/Pf | 14 | suppressed |
| Firdapse | Amifampridine Phosphate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 13 | suppressed |
| Topiramate Er | Topiramate | 13 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 13 | suppressed |
| Actemra | Tocilizumab | 12 | suppressed |
| Austedo Xr | Deutetrabenazine | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 12 | suppressed |
| Enspryng | Satralizumab-Mwge | 12 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Teriflunomide | Teriflunomide | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Trokendi Xr | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $70,387.72 · 317 records | ABBVIE INC. | AMPYRA, AUSTEDO XR, Auvelity, BOTOX, Bafiertam, CAPLYTA, DAYBUE, Dysport, EPIDIOLEX, FIRDAPSE, FYCOMPA, Fintepla, GOMEKLI, General - DBS, HORIZANT, HYQVIA, Hizentra, INBRIJA, KEVEYIS, Motpoly XR, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, Ocrevus Zunovo, PANZYGA, QULIPTA, REXULTI, Radicava, Rystiggo, SKYCLARYS, SPRAVATO, Sunosi, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VRAYLAR, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, XCOPRI, XYWAV, Xeomin | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ampyra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error